Bladder Cancer VL

FDA ALERT: Efficacy Issue Identified in Some Patients Taking Pembrolizumab or Atezolizumab as Monotherapy to Treat Advanced Urothelial Cancer - Petros Grivas

Details
(Length of Discussion: 16 min) Petros Grivas and Alicia Morgans discuss the late-breaking FDA Alert announcing the label changes for Pembrolizumab and Atezolizumab as Monotherapy to Treat Urothelial Cancer with Low Expression of PD-L1. Biographies: Petros Grivas MD, Ph.D. a medical oncologist at Seattle Cancer Care Alliance with expertise in genitourinary cancers such as bladder cancer, prostate c...

Long-term Efficacy with Atezolizumab an IO Update- Arjun Balar

Details
(Length of conversation: 14 minutes) Alicia Morgans and Arjun Balar converse on the long-term efficacy data of atezolizumab in the 1st line setting as well as the 2nd line setting from the single-arm phase 2 trial. Discussion evolves to the recent safety alerts by the FDA highlighting the two studies, Keynote 361 and IMvigor 130. They question the applicability to clinical practice and the challen...

Journey from Oncologist to Cancer Survivor and Patient Advocate - Burton Needles

Details
(Length of Discussion: 12 min) Medical oncologist, bladder cancer survivor, and author of Journey from Oncologist to Cancer Survivor and Patient Advocate in the Era of Precision Medicine, Burt Needles who was diagnosed with a rare form of bladder cancer, plasmacytoid variant in 2013, talks with Alicia Morgans about his unique perspective as a medical oncologist and clinician to a cancer survivor a...

Setting the Stage for the BCG Unresponsive Population - Interview with Ashish Kamat

Details
(Length of Discussion: 11 min) Ashish Kamat, MD, MPH and Alicia Morgans, MD discuss non-muscle invasive bladder cancer, where the field stands particularly for BCG refractory patients and the definition of the BCG unresponsive patient. Ashish overviews the efforts of the SUO-CTC Bladder Committee and important updates and trials in this disease state . Biographies: Ashish M. Kamat, MD Alicia Morga...

Helping Patients Cope after Major Interventions for Bladder Cancer Therapy

Details
(Length of Conversation: 17 min) Stephen Williams and Ashish Kamat discuss the paper, Impact of Psychiatric Illness on Decreased Survival in Elderly Patients with Bladder Cancer in the United States, a study which addresses problems that bladder cancer patients face and the difficulties they experience coping after major interventions for bladder cancer therapy. The conversation also includes reco...

The State of Advanced Bladder Cancer - New Data from AACR 2018 - Interview with Arjun Balar

Details
(Length of Discussion: 30 min) Arjun Balar, MD overviews his presentation from the American Association for Cancer Research Annual Meeting (AACR 2018) meeting on durvalumab plus tremelimumab, combination data in patients with metastatic urothelial cancer. A phase I, Study 10, of data which shows clinical activity with combination treatment in 2nd-line metastatic urothelial carcinoma. A study desig...

Advances in Bladder Cancer - Systemic Therapies Including Immunotherapy - Petros Grivas

Details
(Length of Discussion: 30 min) Petros Grivas and Alicia Morgans discuss the progress in systemic and immunotherapy in advanced bladder cancer. They discuss the biologic and immunologic background of urothelial cancer that paves the way for the development of potential biomarkers, as well as possible therapeutic targets in this disease. They share insights on the significant advances in systemic th...

Minimizing Treatment Burden and Biomarkers in Bladder Cancer - Badrinath Konety

Details
(Length of Interview: 15 min) Badrinath Konety and Alicia Morgans discuss biomarkers in bladder cancer. Concepts highlighted include incorporating clinical and other disease characteristics into biomarkers, so outcomes can be more accurately predicted. Biographies: Badrinath Konety, MD, MBA , is professor and chair at the University of Minnesota, where he holds the Dougherty Family Chair in Uro-On...

A Revolutionizing Time in Immuno-Oncology for Bladder Cancer - Neal Shore

Details
(Length of Discussion: 20 min) There has been a limited number of new therapeutics, particularly in the area of patients who would benefit from advanced systemic bladder cancer treatments. Dr. Neal Shore reviews some pioneering work from the past such as MVAC and gemcitabine platinum based combinations but he notes those treatments are where things were left for many many years. The development of...

Enhanced Recovery After Surgery (ERAS) for Radical Cystectomy: History, Rationale and Programmatic Implementation - Thomas Guzzo

Details
(Length of Discussion: 34 min) Dr. Thomas Guzzo starts his discussion by dialing back to 1997 to share with listeners the beginning of Enhanced Recovery After Surgery (ERAS) and the work of Dr. Kelhlet from Denmark who described multifactorial surgical stress responses such as the pathogenesis of postoperative sleep disturbances as multifactorial, and includes different neural stimulus (surgical s...